ESH MM 2018 | Continuous vs. fixed duration therapy for multiple myeloma?
Jesús San Miguel
Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Jesús San Miguel, MD, PhD, of the University of Navarra, Pamplona, Spain, discusses continuous and fixed duration therapy.
Related videos

Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn

Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter

Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter

Multiple myeloma musings: highlights from 2018 data
Joshua Richter

An exciting era for CAR T-cell therapy
Mohamad Mohty
More from Jesús San Miguel